Development and Validation of the HPLC Method for Quantification of the Innovative Drug DD217, Factor Xa Inhibitor, in Rat Plasma for a Pharmacokinetic Study
Introduction. Nowadays, discovery and development of innovative drugs represent a relevant goal for the pharmaceutical market. One of such drugs is N-(5-chloropyridine-2-yl)-2-({4-[ethanimidoyl(methyl)benzoyl}amino)-5-methylbenzamide hydrochloride (hereinafter DD217), an innovative drug that belongs...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2022-05-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/1235 |